ライフサイエンスコーパス: ophthalmic

1 Ophthalmic admissions were on average shorter in duratio

2 of an EMT-mediated condition using a topical ophthalmic agent.

3 dication use (including, but not limited to, ophthalmic agents and drugs to treat comorbidities) was

4 fsky Performance scores, MRI brain scanning, ophthalmic and audiologic exams, CSF parameters includin

5 nce or absence of ICACs was evaluated in the ophthalmic and cavernous segments of each scan.

6 We report ophthalmic and genetic findings in patients with autosom

7 aflibercept monotherapies were compared with ophthalmic and nonophthalmic direct medical, direct nonm

8 The authors performed 11-year and 2-year ophthalmic and societal cost perspective, cost-utility a

9 ient age, sex distribution, and all baseline ophthalmic and surgical parameters were comparable for t

10 terms associated with known complications of ophthalmic anesthesia.

11 and catheterization type (occlusive into the ophthalmic artery [OA] vs. nonocclusive; P < 0.001) were

12 ptoms, even blindness if the branches of the ophthalmic artery are affected; in these cases, orbital

13 g class 3 retinoblastoma vitreous seeds with ophthalmic artery chemosurgery (OAC) alone versus OAC wi

14 e therapy in patients with retinal artery or ophthalmic artery obstructions.

15 A diagnosis of left ophthalmic artery occlusion was made.

16 Ipsilateral ophthalmic artery was visible in all patients on both pr

17 Patients underwent ophthalmic assessment and retinal imaging including fund

18 Ophthalmic assessment included best-corrected visual acu

19 All patients also had a comprehensive ophthalmic assessment including a detailed history, Ocul

20 Full ophthalmic assessment was performed for members of 3 unr

21 Patients underwent a comprehensive ophthalmic assessment, with DNA from patients and their

22 Patients underwent a comprehensive ophthalmic assessment.

23 ction fraction (OEF), or thickness after the ophthalmic blood vessels have been closed for a substant

24 A quarter of patients referred for ophthalmic care after an ED presentation were LTFU.

25 al principles underlying modern medicine and ophthalmic care as well as the ramifications of our deci

26 their primary clinical responsibilities for ophthalmic care independently.

27 In addition to providing clinical ophthalmic care, many of the respondents have duties tha

28 significantly reduce the burden of inpatient ophthalmic care.

29 vide a range of clinical and some procedural ophthalmic care.

30 A review of well-known ophthalmic case studies by Gass, Irvine, Brockhurst, and

31 d 50-70 years were enrolled at the Zhongshan Ophthalmic Center, a tertiary specialised hospital in Gu

32 1, 2012, to October 31, 2015, at a tertiary ophthalmic center.

33 tive case series included 43 patients from 2 ophthalmic centers in Colombia and Venezuela who underwe

34 llel group trial was done in 87 neonatal and ophthalmic centres in 26 countries.

35 me whose diagnosis was discovered in a neuro-ophthalmic clinic for brain injury.

36 iding complementary information to patients' ophthalmic clinical evaluation and has usefulness as an

37 ory of ocular inflammation or other specific ophthalmic condition before initiation of ICIs were exam

38 nalysis, younger age (P < .001), a nonurgent ophthalmic condition or nonophthalmic primary diagnosis

39 her an admitting or primary diagnosis for an ophthalmic condition using ICD-9-CM codes.

40 e more likely to revisit the ED for the same ophthalmic condition.

41 4 (156.0) days, and 91 (36.4%) had >=1 prior ophthalmic condition.

42 .006), fungal cases (P < .001), and comorbid ophthalmic conditions (P < .001).

43 Outcomes reporting for ophthalmic conditions currently widely varies across hos

44 sed international standard outcomes sets for ophthalmic conditions to metrics currently reported by e

45 s, as well as elderly patients with comorbid ophthalmic conditions, as these patients have worse clin

46 ved understanding of pathophysiology of rare ophthalmic conditions, but alone are insufficient to pro

47 vitamin D levels can exacerbate preexisting ophthalmic conditions, such as diabetes.

48 The average ophthalmic cost perspective CUR for bevacizumab was $11,

49 her formulations for treatment of corneal or ophthalmic cystinosis were included.

50 CSF) opening pressure, treatments, and neuro-ophthalmic data from initial and final visits.

51 Ophthalmic data were collected at baseline and yearly vi

52 lmic Drug Advisory Committee (DODAC) and the Ophthalmic Devices Panel (ODP) of the Food and Drug Admi

53 s for US Medicare beneficiaries with primary ophthalmic diagnoses were for nontraumatic disorders of

54 analyze inpatient admissions with a primary ophthalmic diagnosis from 2001 to 2014.

55 coidosis (4 scans, 3 patients), IgG4-related ophthalmic disease (IgG4-ROD) (5 scans, 3 patients), and

56 , KIR3DL1(LOW)/KIR3DS1 increased the risk of ophthalmic disease (p = 1.2 x 10(-5), OR 3.92, 95% CI 2.

57 PLWH were more likely to have ophthalmic disease at enrollment, but there was no diffe

58 Ophthalmic disease in people living with HIV (PLWH) and

59 on of specific cohorts covering 524 distinct ophthalmic disease types and 1800 disease sub-types acro

60 , and the median follow-up from diagnosis of ophthalmic disease was 23 months.

61 The median age at presentation of ophthalmic disease was 66 years (range, 23-88 years), an

62 ad relatively good acuity; however, advanced ophthalmic disease was associated with reduced acuity.

63 00 enrolled patients per general category of ophthalmic disease, overall and for each available medic

64 whose manipulation could be used to mitigate ophthalmic disease.

65 t inhibition can be used in the treatment of ophthalmic disease.

66 comprehensive and accurate knowledgebase of ophthalmic diseases containing curated clinical, treatme

67 The knowledgebase captures ophthalmic diseases in a genetically diverse population

68 ir versatile application in the treatment of ophthalmic diseases, including age-related macular degen

69 Ophthalmic diseases, such as age-related macular degener

70 l vision research through a knowledgebase of ophthalmic diseases.

71 ental factors contributing to or influencing ophthalmic diseases.

72 ivo spectroscopy of the eye, for a number of ophthalmic diseases.

73 is correlated with the diagnosis of several ophthalmic diseases.

74 positively impact visual acuity outcomes in ophthalmic diseases.

75 Cataract is a common ophthalmic disorder and the leading cause of blindness w

76 investigate the frequency and prevalence of ophthalmic disorders for ophthalmologist visits in adult

77 , but there was no comprehensive analysis of ophthalmic disorders of patients with SLE using populati

78 shed light on the genetic findings for other ophthalmic disorders such as glaucoma and other optic ne

79 In addition, the risk of several SLE related ophthalmic disorders, including episcleritis and sclerit

80 of a deep-learning algorithm for diagnosing ophthalmic disorders.

81 odern diagnostic workflows for heterogeneous ophthalmic disorders.

82 ch may be applicable in other rare childhood ophthalmic disorders.

83 spective analysis included 396 patients with ophthalmic DLBCL from January 1, 1973, through December

84 y 17.7%, and overall survival was greater in ophthalmic DLBCL than in DLBCL located outside the centr

85 nvestigated meetings of the Dermatologic and Ophthalmic Drug Advisory Committee (DODAC) and the Ophth

86 and boost the future trends in the field of ophthalmic drug discovery.

87 Concurrently, minority Americans had more ophthalmic emergency department visits but lower cost pe

88 ve of DED and prescriptions for cyclosporine ophthalmic emulsion identified a DED population from 9.7

89 y codes and prescriptions for cyclosporine A ophthalmic emulsion were used to identify patients with

90 e drug distribution and diffusion in complex ophthalmic emulsions and assist with formulation design

91 e method to support regulatory assessment of ophthalmic emulsions and formulation development.

92 Establishing bioequivalence (BE) of ophthalmic emulsions in the absence of in vivo data is c

93 istribution and mechanism of drug release of ophthalmic emulsions in the context of factors associate

94 in vitro methods to support BE assessment of ophthalmic emulsions.

95 defective vision (55.2%) followed by routine ophthalmic evaluation (13%).

96 Extensive preoperative ophthalmic evaluation and meticulous postoperative infla

97 Our study indicates the importance of serial ophthalmic evaluation in all cases of CVST.

98 The same ophthalmic evaluation was performed at each follow-up vi

99 Among patients referred for follow-up ophthalmic evaluation, the adherence rate was 55.4% at 1

100 Demographic data collection, ophthalmic evaluation, ultrasound scan, and systemic stu

101 ning results were referred for comprehensive ophthalmic evaluation.

102 verread, and were not referred for follow-up ophthalmic evaluation.

103 Patients underwent ophthalmic evaluations including visual testing, optical

104 Follow-up ophthalmic evaluations, including ophthalmic ultrasound

105 All participants underwent complete ophthalmic evaluations.

106 Clinical ophthalmic exam and MRI studies were significant for rig

107 Visual acuity (VA), ophthalmic exam results and treatments were recorded.

108 l current spectacle users underwent detailed ophthalmic examination and refraction.

109 Patients underwent a full ophthalmic examination at each visit.

110 stemic immunosuppressive therapy and have an ophthalmic examination at Mayo Clinic Rochester.

111 Specifically, we recommend an ophthalmic examination at the time of initial diagnosis,

112 All patients underwent comprehensive ophthalmic examination before aqueous humor dynamics stu

113 imulating a "no-talking" policy, while in an ophthalmic examination chair with an blood agar plate se

114 Baseline, demographic, procedural, and ophthalmic examination data were recorded at the time of

115 Ophthalmic examination included best corrected visual ac

116 All patients underwent ophthalmic examination including psychophysical tests, e

117 Ophthalmic examination is recommended in patients with c

118 Therefore, ophthalmic examination may be a valuable method to disti

119 Participants underwent an ophthalmic examination that included OCT imaging of the

120 Boston Children's Hospital for CS who had an ophthalmic examination that included pattern reversal (p

121 Complete ophthalmic examination was performed by an expert ophtha

122 Detailed ophthalmic examination was performed in seven sporadic a

123 The remaining ophthalmic examination was unremarkable.

124 oscopic disc photographs, and details of the ophthalmic examination were obtained and transferred to

125 nual follow-up visit, all subjects underwent ophthalmic examination with assessment of best-corrected

126 All patients underwent complete ophthalmic examination with multimodal imaging, includin

127 nts were evaluated by a thorough history and ophthalmic examination with selected laboratory testing

128 visual impairment and findings from clinical ophthalmic examination, advanced retinal imaging, and el

129 All participants underwent complete ophthalmic examination, color fundus photography (used f

130 All subjects (n = 42) underwent a complete ophthalmic examination, computer videokeratography, and

131 e) were recruited to undergo a comprehensive ophthalmic examination, including BCVA measurement, post

132 icipants were evaluated with a comprehensive ophthalmic examination, including best-corrected visual

133 Participants underwent ophthalmic examination, including uncorrected visual acu

134 Participants underwent a detailed ophthalmic examination, including visual acuity assessme

135 At each follow-up visit, a complete ophthalmic examination, including visual acuity, IOP, sl

136 ounger than 10 years, undergo annual dilated ophthalmic examination, looking for evidence of CBME, si

137 itudinal clinical evaluation, including full ophthalmic examination, multimodal retinal imaging, peri

138 underwent a single study visit with dilated ophthalmic examination, OCT angiography (OCTA), and fluo

139 end points included adverse event reporting, ophthalmic examination, physical examination, and labora

140 e compared by demographics, body mass index, ophthalmic examination, treatment, clinical course, and

141 All patients underwent full ophthalmic examination.

142 ventions or Observation Procedures: Complete ophthalmic examination.

143 mily were recruited and underwent a detailed ophthalmic examination.

144 Comprehensive ophthalmic examinations and IOP assessments through the

145 ived complete preoperative and postoperative ophthalmic examinations for first eye and second eye cat

146 al histories were obtained and comprehensive ophthalmic examinations were conducted for all of the ey

147 ss than 1251 g at birth underwent sequential ophthalmic examinations, beginning at age 4 to 6 weeks,

148 ere assessed from comprehensive systemic and ophthalmic examinations, interviews, and laboratory inve

149 Ophthalmic examinations, OCT, and ocular tolerability an

150 Ophthalmic examinations, optical coherence tomography (O

151 d family members who underwent comprehensive ophthalmic examinations.

152 ring their encounter or obtained from recent ophthalmic examinations.

153 The mothers of all the children had no ophthalmic findings and did not report ocular symptoms d

154 We reviewed the neuro-ophthalmic findings and visual outcomes in a large serie

155 The ophthalmic findings included vitreous amyloid (26/26, 10

156 Ophthalmic findings of 9 patients from 3 families with t

157 We report the ophthalmic findings of a patient with type Ia glycogen s

158 Ophthalmic findings were divided into grades of severity

159 Of the 29 patients with neuro-ophthalmic findings, the median age was 67 years (range,

160 otype data were collected over the course of ophthalmic follow-up, spanning a period of 20 years, beg

161 Using ophthalmic fundus imaging and computational modeling, we

162 DR) interpreted by trained nonmedical staff (ophthalmic graders) to detect reactivation of disease wa

163 tion has the potential to offer insight into ophthalmic health and disease that is complementary to t

164 Ophthalmic history, best-corrected visual acuity, spectr

165 edical records data from Narayana Nethralaya ophthalmic hospital recorded in the MS-SQL database was

166 ession was used to determine odds of primary ophthalmic hospitalization after controlling for patient

167 ercent agreement with clinical diagnosis, no ophthalmic imaging method conclusively differentiated pa

168 Prospective Intraoperative and Perioperative Ophthalmic Imaging with Optical Coherence Tomography (PI

169 Detailed study of ophthalmic immune-related adverse events (AEs), includin

170 rates for anterior uveitis, the most common ophthalmic immune-related AE, were 8209 per 100 000 for

171 were identified, 112 of whom demonstrated an ophthalmic immune-related AE.

172 IRRs) were derived by comparing incidence of ophthalmic immune-related AEs after ICIs versus rates of

173 dition demonstrated high recurrence rates of ophthalmic immune-related AEs after initiating ICIs (up

174 Rates of ophthalmic immune-related AEs among patients receiving I

175 pecialist care is important because rates of ophthalmic immune-related AEs are elevated compared with

176 Rates of ophthalmic immune-related AEs in patients with a past hi

177 Patients with select ophthalmic immune-related AEs were identified by Interna

178 Incidence of ophthalmic immune-related AEs within 1 year after initia

179 due to any cause but without significant non-ophthalmic impairments.

180 etina barrier, using a panel of interrelated ophthalmic in vivo imaging measures in a mouse model of

181 ic membrane (AM) is used to treat a range of ophthalmic indications but must be presented in a non-co

182 the Ocular Response Analyzer (ORA; Reichert Ophthalmic Instruments Inc, Depew, New York, USA).

183 with the Ocular Response Analyzer (Reichert Ophthalmic Instruments, Buffalo, NY).

184 rm ocular sequelae, and duration and type of ophthalmic intervention.

185 ated with novel combinations of non-invasive ophthalmic interventions.

186 tudy participants included all patients with ophthalmic issues in British Columbia, such as those of

187 implanted in 36 eyes, and a Molteno (Molteno Ophthalmic Limited) glaucoma implant was implanted in 3

188 the Molteno3 glaucoma implant (MGI) (Molteno Ophthalmic Limited, Dunedin, New Zealand).

189 Additional ophthalmic manifestations included reduced brow hair, ma

190 Ophthalmic manifestations increased in severity with inc

191 Ophthalmic manifestations of CLN3 disease correlate clos

192 Ophthalmic manifestations of congenital Zika syndrome.

193 Ophthalmologists should be aware of the ophthalmic manifestations of DICER1 syndrome, and indivi

194 The visual sequelae of these ophthalmic manifestations remain unknown.

195 of 29 CRMP5 IgG-positive patients with neuro-ophthalmic manifestations, optic neuropathy presented wi

196 nine of 76 patients (38%) demonstrated neuro-ophthalmic manifestations.

197 All patients had bilateral ophthalmic manifestations.

198 Ophthalmic measures included intraocular pressure, visua

199 11-year direct ophthalmic medical costs expended for bevacizumab, ranib

200 From an ophthalmic (medical) cost perspective, bevacizumab, rani

201 Total ophthalmic medication expenditure in the United States i

202 2.7%) medications accounted for 72.2% of all ophthalmic medication expenditures.

203 2016, 9989 MEPS participants (4.2%) reported ophthalmic medication prescription use.

204 Annual ophthalmic medication use increased from 10.0 to 12.2 mi

205 % CI, 4%-6%) fewer surgical patients used an ophthalmic medication.

206 Ophthalmic medications (OR = 0.28, P < .001), non-opioid

207 rs' Medicare Part D prescribing patterns for ophthalmic medications and to estimate the potential sav

208 If Medicare negotiated the prices for ophthalmic medications at USVA rates, $1.09 billion woul

209 this same period, national expenditures for ophthalmic medications increased from $3.39 billion to $

210 more likely to have greater OOP spending on ophthalmic medications.

211 Cases were identified by the Ophthalmic Mutual Insurance Company from closed case fil

212 ained personnel to identify individuals with ophthalmic needs, focusing on African Americans >/=50 ye

213 melanoma would benefit from evaluation by an ophthalmic oncologist.

214 up of members of the American Association of Ophthalmic Oncologists and Pathologists (AAOOP) with sup

215 Expert panel of ophthalmic oncologists, pathologists, and geneticists.

216 management of OSA as well as ICH to optimize ophthalmic outcomes.

217 t in the diagnosis and management of various ophthalmic pathologies.

218 Twelve ophthalmic pathologists analyzed scanned hematoxylin and

219 Most ophthalmic patients were emergent admissions (73.19%) wi

220 yze the correlations between XP genotype and ophthalmic phenotype.

221 it is still unclear if and how it can affect ophthalmic physiology.

222 2 Victorian tertiary hospitals and 1 private ophthalmic practice.

223 Bandage contact lenses are commonly used by ophthalmic practitioners to protect the patient's cornea

224 ted trends in national and per capita annual ophthalmic prescription expenditures by pooling data int

225 ce Measure (POEM) modified for an Australian ophthalmic private clinical practice setting.

226 e associated with a risk of other associated ophthalmic problems.

227 A total of 31.1% of all patients had an ophthalmic procedure, pars plana vitrectomy (4.8%) being

228 en after combined cases (cataract with other ophthalmic procedures) than after standalone cataract su

229 possibly better tolerated antimicrobial for ophthalmic procedures.

230 The objective of this study was to design an ophthalmic rating scale for CLN3 disease in order to qua

231 The newly established Hamburg CLN3 ophthalmic rating scale may serve as an objective marker

232 trong correlation was found between the CLN3 ophthalmic rating scale score and the Hamburg JNCL score

233 A handheld ophthalmic readout device comprising light-emitting diod

234 cated outside the central nervous system and ophthalmic regions.

235 real antibiotics is consistent with previous ophthalmic reports regarding other corynebacteria, as we

236 l hemodynamics remains an unmet challenge in ophthalmic research.

237 We compared ophthalmic resource utilization and costs over 2 years o

238 nsus statement from the panel: (1) Dedicated ophthalmic screening is recommended for all children at

239 We propose an ophthalmic screening protocol to diagnose retinitis in p

240 m was formed to review the literature and an ophthalmic screening protocol was developed.

241 Ophthalmic screening to check for diabetic retinopathy (

242 hreshold for intervention to avoid permanent ophthalmic sequelae and possible blindness.

243 nicipalities with fewer inhabitants and less ophthalmic services.

244 amera by trained general physicians in a non-ophthalmic setting.

245 The mean ophthalmic severity grade was 2.4 (range, 0-3).

246 Hg at 8:00 AM) were randomized to netarsudil ophthalmic solution 0.02% QD (PM) or timolol ophthalmic

247 ophthalmic solution 0.02% QD (PM) or timolol ophthalmic solution 0.5% BID.

248 ular and systemic safety of netarsudil 0.02% ophthalmic solution, a rho-kinase inhibitor and norepine

249 patients in the use of original and generic ophthalmic solutions.

250 P Koirala Lions Centre for Ophthalmic Studies (BPKLCOS) among patients receiving in

251 nical, treatment and imaging data of 581,466 ophthalmic subjects from the Indian population, recorded

252 tiating ICI therapy, early coordination with ophthalmic subspecialist care is important because rates

253 on was $977 476; the median award across all ophthalmic subspecialties was $568 302 (P = 0.25).

254 The presence of an ophthalmic surgeon (OR, 16.3; P < 0.001) significantly a

255 ationality, location, and the presence of an ophthalmic surgeon as independent variables.

256 Ophthalmic surgeons have been overwhelmed by the influx

257 Of 5349 ophthalmic surgeries performed during the 2 assessment p

258 er age, cataract surgery combined with other ophthalmic surgeries, and anterior vitrectomy.

259 ity worse than 20/40, multifocal lens, prior ophthalmic surgeries, and prior ocular trauma.

260 procedures versus those combined with other ophthalmic surgeries.

261 OCT Visualization during En Face Retinal and Ophthalmic Surgery (DISCOVER) intraoperative OCT study i

262 OCT Visualization During En Face Retinal and Ophthalmic Surgery (DISCOVER) study is a single-site, mu

263 gery and procedures (62.5%) and assisting in ophthalmic surgery and minor procedures (65.0%).

264 duties that involve consenting patients for ophthalmic surgery and procedures (62.5%) and assisting

265 andardized opioid prescribing guidelines for ophthalmic surgery at an academic institution.

266 The presence of blood during ophthalmic surgery is problematic, as it can obstruct a

267 cities returned to the operating room for an ophthalmic surgery other than cataract extraction 3.7% o

268 nes reduces overprescribing of opioids after ophthalmic surgery without increasing refill rates.

269 radiation, general surgery, neurosurgery, or ophthalmic surgery, reducing treatment abandonment, and

270 ike the hyaluronic acid gel commonly used in ophthalmic surgery, SPG-178 did not permit the ingress o

271 study characterized the delivery of emergent ophthalmic surgical care during April 2020 of the corona

272 nce to support the maintenance of specialist ophthalmic surgical competencies in deployed coalition M

273 ss of a pipeline for automated extraction of ophthalmic surgical outcomes from EHR to answer key clin

274 Exclusion criteria were any ophthalmic surgical procedures within the preceding 6 mo

275 cacy and safety of once-daily nepafenac 0.3% ophthalmic suspension versus vehicle, based on clinical

276 Neuro-ophthalmic symptoms occurred before the diagnosis of can

277 no published reports focusing upon the neuro-ophthalmic symptoms that might occur in EDS patients aft

278 ntation, resulted in a complete remission of ophthalmic symptoms.

279 ondition that we suggest calling, "astronaut ophthalmic syndrome." We maintain that this condition is

280 The ophthalmic system enables the assessment of dry eye seve

281 obtained from the Galilei G4 device (Ziemer Ophthalmic Systems AG, Port, Switzerland) in 31 clinical

282 low-energy femtosecond laser (LDV Z8; Ziemer Ophthalmic Systems, Port, Switzerland) and combined with

283 er necessary, including an IOP check with an ophthalmic technician or non-retinal eye care provider.

284 el; and 3) by regular clinic protocol, by an ophthalmic technician.

285 abstracts and yielded 43 articles, which the Ophthalmic Technology Assessment Committee Oculoplastics

286 and were deemed clinically relevant for the Ophthalmic Technology Assessment Committee Retina/Vitreo

287 ch strategy was designed to update the first Ophthalmic Technology Assessment on endonasal DCR from 2

288 esponse with respect to patient symptoms and ophthalmic testing.

289 Ophthalmic tests were conducted most frequently in the G

290 Ophthalmic treatment included external beam radiation (3

291 rbidity than intraocular injection, but many ophthalmic treatments are unable to enter the eye or rea

292 y (IVFA), indocyanine-green angiography, and ophthalmic ultrasound (B-scan) billed in the Medicare fe

293 Follow-up ophthalmic evaluations, including ophthalmic ultrasound and fundus photography, were perfo

294 t was diagnosed in the community by a mobile ophthalmic unit and patients were referred to a hospital

295 , India) is the only approved biosimilar for ophthalmic use, but the landscape will rapidly change in

296 ge pattern as anterior (A-CCF: draining into ophthalmic veins) and posterior (P-CCF: not draining int

297 ins) and posterior (P-CCF: not draining into ophthalmic veins).

298 We ligated the ophthalmic vessels for 120 minutes in one eye of 17 rats

299 by a sub-perfluorocarbon liquid injection of ophthalmic viscoelastic device (OVD) technique.

300 between varicella zoster virus reactivation (ophthalmic zoster) and incident dementia (HR 2.97; 95%CI